BR9913201A - Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica - Google Patents

Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica

Info

Publication number
BR9913201A
BR9913201A BR9913201-0A BR9913201A BR9913201A BR 9913201 A BR9913201 A BR 9913201A BR 9913201 A BR9913201 A BR 9913201A BR 9913201 A BR9913201 A BR 9913201A
Authority
BR
Brazil
Prior art keywords
treatment
chronic fatigue
fatigue syndrome
substance
fibromyalgia
Prior art date
Application number
BR9913201-0A
Other languages
English (en)
Inventor
Wolfgang Mueller
Thomas Stratz
Lothar Faerber
Original Assignee
Novartis Ag
Wolfgang Mueller
Thomas Stratz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818467.4A external-priority patent/GB9818467D0/en
Priority claimed from GBGB9826692.7A external-priority patent/GB9826692D0/en
Application filed by Novartis Ag, Wolfgang Mueller, Thomas Stratz filed Critical Novartis Ag
Publication of BR9913201A publication Critical patent/BR9913201A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"USO DE ANTAGONISTAS DA SUBSTâNCIA P PARA O TRATAMENTO DA SìNDROME DA FADIGA CRÈNICA E/OU FIBROMIALGIA E USO DE ANTAGONISTAS DO RECEPTOR DE NK-1 PARA TRATAMENTO DA SìNDROME DA FADIGA CRÈNICA"<D>. A invenção refere-se ao uso farmacêutico de antagonistas da substância P específicos, em particular antagonistas 1-acilpiperidina da substância P, especialmente, N-benzoil-2-benzil-4-(azanaftoil-amino)-piperidinas, por exemplo, de fórmula onde X e Y são cada qual, independentemente entre si N e/ou CH e o anel A é não-substituído ou mono- ou polissubstituído por substituintes selecionados do grupo que consiste em alquila inferior, alcóxi inferior, halogênio, nitro e trifluormetila; e sais farmaceuticamente aceitáveis dos mesmos no tratamento da síndrome da fadiga crónica (CFS) na ausência de terapia inibidora da reabsorção de serotonina seletiva/agonista de serotonina ou para o tratamento de fibromialgia ou de sintomas funcionais associados.
BR9913201-0A 1998-08-25 1999-08-24 Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica BR9913201A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9818467.4A GB9818467D0 (en) 1998-08-25 1998-08-25 Organic compounds
GBGB9826692.7A GB9826692D0 (en) 1998-12-04 1998-12-04 Organic compounds
PCT/EP1999/006215 WO2000010545A2 (en) 1998-08-25 1999-08-24 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
BR9913201A true BR9913201A (pt) 2001-05-08

Family

ID=26314255

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913201-0A BR9913201A (pt) 1998-08-25 1999-08-24 Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica

Country Status (14)

Country Link
US (5) US20030092735A1 (pt)
EP (1) EP1107744B1 (pt)
JP (1) JP4510290B2 (pt)
CN (1) CN1216598C (pt)
AT (1) ATE238044T1 (pt)
AU (1) AU5624599A (pt)
BR (1) BR9913201A (pt)
CA (1) CA2339628C (pt)
DE (1) DE69907220T2 (pt)
DK (1) DK1107744T3 (pt)
ES (1) ES2198948T3 (pt)
PT (1) PT1107744E (pt)
TW (1) TW200529847A (pt)
WO (1) WO2000010545A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274604B1 (en) 1996-07-17 2001-08-14 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
EP1107744B1 (en) * 1998-08-25 2003-04-23 Novartis AG Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
UA76810C2 (uk) 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
GB0220953D0 (en) 2002-09-10 2002-10-23 Novartis Ag Organic compounds
US7295500B2 (en) * 2002-09-30 2007-11-13 Nec Corporation Recording condition setting method and information recorder using same
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
CN101668527A (zh) * 2007-02-23 2010-03-10 阿韦拉制药股份有限公司 药物制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
AU648317B2 (en) * 1990-06-01 1994-04-21 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
JPH05262654A (ja) * 1992-03-18 1993-10-12 Kaken Pharmaceut Co Ltd 慢性疲労症候群治療剤
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
JP3925662B2 (ja) * 1995-01-12 2007-06-06 グラクソ，グループ，リミテッド タキキニンアンタゴニスト活性を有するピペリジン誘導体
WO1996024353A1 (en) 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
AU2611297A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Bisindoles for treating pain or nociception
US5891875A (en) * 1996-05-20 1999-04-06 Eli Lilly And Company Morpholinyl tachykinin receptor antagonists
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
WO1998024438A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
EP1107744B1 (en) * 1998-08-25 2003-04-23 Novartis AG Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia

Also Published As

Publication number Publication date
US20100055176A1 (en) 2010-03-04
CN1348372A (zh) 2002-05-08
US20030092735A1 (en) 2003-05-15
CN1216598C (zh) 2005-08-31
CA2339628C (en) 2008-06-03
JP4510290B2 (ja) 2010-07-21
EP1107744B1 (en) 2003-04-23
DE69907220D1 (de) 2003-05-28
DE69907220T2 (de) 2004-02-05
TW200529847A (en) 2005-09-16
WO2000010545A3 (en) 2000-08-10
US20080161329A1 (en) 2008-07-03
WO2000010545A2 (en) 2000-03-02
PT1107744E (pt) 2003-08-29
US7713984B2 (en) 2010-05-11
US20050096334A1 (en) 2005-05-05
DK1107744T3 (da) 2003-07-28
CA2339628A1 (en) 2000-03-02
EP1107744A2 (en) 2001-06-20
JP2002523363A (ja) 2002-07-30
US20070155759A1 (en) 2007-07-05
ATE238044T1 (de) 2003-05-15
ES2198948T3 (es) 2004-02-01
AU5624599A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
Schreiber et al. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the ‘atypical’antipsychotics, clozapine and risperidone
BRPI0414450A (pt) derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica
NO20032253D0 (no) Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer
DK0760811T3 (da) Imidazolderivater som histaminreceptor H3-modulatorer
ITRM20010356A1 (it) &#34;5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
BRPI0418102A (pt) derivados de quinolina
DE602004021921D1 (de) Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
NO20061737L (no) Aminosubstituerte erylamino B2 adrenergiske receptoragonister
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
BR0311436A (pt) Derivados de 1-(aminoalquil)-3-sulfoni-lindol e -indazol como ligandos da 5-hidroxitriptamina-6
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
ATE399770T1 (de) Tachykininrezeptorantagonisten
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
NO985599D0 (no) Arylsubstituerte, sykliske aminer som selektive dopamin D3-ligander
BR0316895A (pt) Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto
BR0007718A (pt) Utilização de derivados depiridazino[4,5-b]indol-1-acetamida para preparaçãode medicamentos para doenças ligadas à disfunçãode receptores de benzodiazepina do tipoperiférico
WO1993012754A3 (en) Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
WO2000010545A3 (en) Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
BR0111279A (pt) Derivados da ciclohexilamina como antagonistas para o receptor do nmda seletivo ao subtipo
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
MEP19108A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
DE60009544D1 (de) Il-8 rezeptor antagonisten
BR9714215A (pt) Derivados de benzoato de 1,4-diazabiciclo[2.2.2]oct-2-ilmetila, seu preparo e sua aplicação em terapêutica
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/4468, A61K 31/4709, A61K 31/4725, A61K 31/517, A61P 25/04, A61P 29/02, A61P 43/00

Ipc: A61K 31/4468 (2007.10), A61K 31/4709 (2007.10), A6

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI.

B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]

Free format text: REFERENTE A RPI 2043 DE 02/03/2010.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]